Pristimerin, a traditional Chinese medicine, significantly decreased the AEG-1, FANCD2 and FANCI levels in endometrial cancer cells and restored their sensitivity to cisplatin in an in vivo xenograft model [184]. The gene discussed is MTDH; the disease is endometrial cancer.